Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralmitaront PET Study in Schizophrenia
NCT06880328Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ralmitaront in schizophrenia (2 arms), sponsored by Roche. Primary endpoint: Influx Rate Constant (Ki) Value of [18F]-DOPA in the Whole Striatum. Started Nov 2018; status: completed.
02
Drugs
ralmitaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06880328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880328.